Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function

ABSTRACTThe development of specific, safe, and potent monoclonal antibodies (Abs) has led to novel therapeutic options for infectious disease. In addition to preventing viral infection through neutralization, Abs can clear infected cells and induce immunomodulatory functions through engagement of th...

Full description

Bibliographic Details
Main Authors:	Jennifer L. Schwedler, Maxwell A. Stefan, Christine E. Thatcher, Peter R. McIlroy, Anupama Sinha, Ashlee M. Phillips, Christopher A. Sumner, Colleen M. Courtney, Christina Y. Kim, Dina R. Weilhammer, Brooke Harmon
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Antibody dependent cell-mediated cytotoxicity (ADCC) antibody therapy complement complement dependent cytotoxicity (CDC) Fc effector function Fc-engineering
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2023.2297451

Similar Items

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
by: Rena Liu, et al.
Published: (2020-11-01)

IgG Fc engineering to modulate antibody effector functions
by: Xinhua Wang, et al.
Published: (2017-10-01)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
by: Sophia Roßkopf, et al.
Published: (2020-11-01)

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
by: Patricia Gogesch, et al.
Published: (2021-08-01)

Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections
by: Sai Priya Anand, et al.
Published: (2019-08-01)

Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection
by: Ming Yang, et al.
Published: (2023-03-01)

Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques
by: Marina Tuyishime, et al.
Published: (2023-12-01)

Editorial: Effector functions of therapeutic antibodies
by: Peter Boross, et al.
Published: (2023-01-01)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
by: Ruixiao Du, et al.
Published: (2023-12-01)

The role of N-glycosylation in B-cell biology and IgG activity. The aspects of autoimmunity and anti-inflammatory therapy
by: Sara Trzos, et al.
Published: (2023-07-01)

A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity
by: Hee-Jeong Youk, et al.
Published: (2022-06-01)

Understanding Fc function for rational vaccine design against pathogens
by: Kathryn A. Bowman, et al.
Published: (2024-01-01)

Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
by: Shamus P. Keeler, et al.
Published: (2021-05-01)

Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement
by: Zenjiro Sampei, et al.
Published: (2023-05-01)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
by: Josée Golay, et al.
Published: (2020-10-01)

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
by: Andréa Cottignies-Calamarte, et al.
Published: (2023-02-01)

Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection
by: Zhiqiang Zheng, et al.
Published: (2020-01-01)

Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods
by: Christophe Dumet, et al.
Published: (2023-03-01)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with <i>KRAS</i> p.G13D Mutation
by: Tomokazu Ohishi, et al.
Published: (2020-08-01)

Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
by: Aleksandra Kusowska, et al.
Published: (2022-01-01)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
by: Kate J. Dixon, et al.
Published: (2021-01-01)

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
by: Kwong yok Tsang, et al.
Published: (2022-06-01)

Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
by: Jamie Valeich, et al.
Published: (2020-09-01)

Effector mechanisms of influenza-specific antibodies: neutralization and beyond
by: Federica Sicca, et al.
Published: (2018-09-01)

Bispecific mAb<sup>2</sup> Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
by: Katharina Stadlbauer, et al.
Published: (2022-05-01)

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
by: Brian C. Mackness, et al.
Published: (2019-10-01)

The Role of Trogocytosis in the Modulation of Immune Cell Functions
by: Kensuke Miyake, et al.
Published: (2021-05-01)

Vaccination with the Crimean-Congo hemorrhagic fever virus viral replicon vaccine induces NP-based T-cell activation and antibodies possessing Fc-mediated effector functions
by: F. E. M. Scholte, et al.
Published: (2023-08-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design
by: Sinthujan Jegaskanda, et al.
Published: (2017-06-01)

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants
by: Robert Pejchal, et al.
Published: (2023-08-01)

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityResearch in context
by: Ida H. Hiemstra, et al.
Published: (2023-07-01)

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice
by: Abenaya Muralidharan, et al.
Published: (2022-11-01)

Alteration in Leukocyte Subsets and Expressions of FcγR and Complement Receptors among Female Ragpickers in Eastern India
by: Nandan K. Mondal, et al.
Published: (2017-06-01)

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
by: Gilles Thibault, et al.
Published: (2021-06-01)

Monoclonal Antibodies in Cancer Therapy
by: David Zahavi, et al.
Published: (2020-07-01)

Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice
by: Rebekah Sherburn, et al.
Published: (2020-09-01)

Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects
by: Dhuha H Nawab
Published: (2021-12-01)

A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC
by: Huiting Wu, et al.
Published: (2023-12-01)

Multivalent Rhamnose‐Modified EGFR‐Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies
by: Yanchun Li, et al.
Published: (2024-04-01)